Industry Insights

• 
  2025 Q1: Oncology Business Competition Among MNCs Xiaobin
  June 04, 2025
  How did MNCs fare in the oncology field during Q1 of this year?
• 
  Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
  April 28, 2025
  This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
• 
  Taking Over the "King of Medicine"? Chinese Enterprises Lead the Development of PD-(L)1/VEGF Bispecific Antibody Antitumor Drug Kevin
  April 28, 2025
  PD-(L)1 and VEGF (vascular endothelial growth factor) bispecific antibody therapies are considered a key direction for future tumor treatments, attracting increasing global interest due to their unique mechanism of action and promising clinical data.

• 
  Oral Solid Dosage Forms: How to Ensure Compliance and Efficacy Saher Haider
  June 04, 2025
  Oral solid dosage forms (OSDs) comprise 66% to 70% of all prescribed and dispensed products worldwide.

• 
  Alzheimer’s Disease: Charting the Course from Plaques to Promise Muhammad Farhan Khalid
  May 28, 2025
• 
  InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China PharmaSources
  May 16, 2025
• 
  Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China ACN Newswire
  May 07, 2025
  Everest Medicines announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA).

• 
  Popular Products and Companies at PharmaSources.com (January 2025) PSI
  January 15, 2025
  Popular Products and Companies at PharmaSources.com
• 
  Research and Application of Artemisia Argyi Xiaonisha
  August 12, 2024
• 
  Research Progress on the Application of Biologics in Pediatric Asthma Xiaomichong
  July 19, 2024

• 
  Apeloa Pharmaceutical releases first ESG PharmaSources
  May 12, 2025
  Apeloa Pharmaceutical has released its first sustainability report. Apeloa’s 2024 Environmental, Social and Governance (ESG) report marks the start of continuous and responsible disclosure into the future.